ABT-737

Catalog No.S1002

ABT-737 Chemical Structure

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 384 In stock
USD 120 In stock
USD 200 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 94 Publications

17 Customer Reviews

  • Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.

    Nat Med 2013 19(11), 1478-88. ABT-737 purchased from Selleck.

    Release of mitochondrial cytochrome c and loss of mitochondrial membrane potential after exposure to ABT-737 (100nM) for 2 hours were assessed by immunohistochemistry and staining with TMRE (red, top panels) and anti-CD41/FITC (green, top panels). Bar represents 5 um. Note that control cells display spreading on glass slides, whereas ABT-737-treated cells do not.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

  • Platelets were incubated in HBS with or without ABT-737 (100nM) for 2 hours before analysis by immunohistochemistry and confocal microscopy. Actin was stained using phalloidin/Alexa-488 (green), and tubulin was stained using anti-tubulin/phycoerythrin (red). Bar represents 5 uM.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

    BCL-XL mediates human neutrophil survival. PMNs were preincubated with the BH3 mimetic ABT-737 (1–10 μM), then cultured in normoxia (gray bars) with or without GM-CSF (500 U/ml) or hypoxia (white bars)or 20 hours, and apoptosis was assessed by morphology (n = 4).

     

     

    J Clin Invest 2011 121, 1053-1063. ABT-737 purchased from Selleck.

  • Analysis of SW480 and SW620 cell sensitivity to the BH3-mimetic ABT-737. (a, b) Percentage of apoptosis in adherent or suspended SW480 (a) or SW620 (b) cells cultured in the presence (ABT-737) or absence (ctrl) of ABT-737 (1 uM).

    Cell Death Dis 2013 4, e801. ABT-737 purchased from Selleck.

    (B) The sensitivity (LD50) of CLL cells, assessed by annexin V staining after 48 h of treatment with ABT‐737, ABT‐263 or ABT‐199, was plotted against the pBcl‐2/Bcl‐2, Mcl‐1/Bcl‐2 and (pBcl‐2 + Mcl‐1)/Bcl‐2 ratios. Relative protein quantification was carried out with kodak carestream molecular imaging software and normalized to β‐actin. Spearman's correlation (r) and P values are shown. Data shown are representative of five independent experiments.

    Br J Pharmacol, 2016, 173(3):471-83. ABT-737 purchased from Selleck.

  • Bcl-XL/Bcl-2 inhibitor ABT-737 aggravates the proapoptotic effects of IL-1IFN-. INS-1E cells were transfected with single or smart Pool PUMA siRNAs and exposed to ABT-737 for 24 h. At this time point, cell death was measured by HO/PI, n  3. *, p  0.05; **, p  0.01.
     

     

     

    J Biol Chem 2010 285, 19919-19920. ABT-737 purchased from Selleck.

    Effect of ABT-737 on the cell viability of CCRF-CEM cells by treatments of AY4 (10 μg/ml), TRAIL (0.5 μg/ml), SAHA (1 μM),VPA (1 mM), or ABT-737 (10 μM) alone or in combination for 24 h prior to MTT assay.

     

     

    Apoptosis 2010 15, 1256-1269. ABT-737 purchased from Selleck.

  • Effects of ABT-737 and RES, applied alone and in combination, on the viability of MOLT-4 cells.

    Toxicol In Vitro, 2017, 42:38-46. ABT-737 purchased from Selleck.

    Upper panel ABT-737 inhibits TFK-1 and EGI-1 cell growth.Cells were exposed to ABT-737 at a concentration ranging from 1 to 50 lM. Following 72 h of incubation, growth inhibition was analyzed by crystal violet assay. Dose–effect plot of ABT-737 treatment is presented.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

  • Lower panel detection of PARP-1, cleaved caspase-9 and caspase-3, BCL-2 and MCL-1 in TFK-1 and EGI-1 cells after 72 h of ABT-737 treatment (1, 3, 10, 25,50 μM). Cell lysates were analyzed on Western blotting.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

    GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells . Breast cancer cell lines were incubate d for 48 hours with 10μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.(A) Suboptimal concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the mock-treated condition.

    Biochem Biophys Res Commun 2013 408, 344-9. ABT-737 purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2012 408, 344-9. ABT-737 purchased from Selleck.

    3 μM ABT737 inhibited growth and viability of TF-1 cells and potentiated proapoptotic effects of 1 μM BIO after 72 hours treatment. TF-1 cells treated with both drugs exhibited more apoptotic cells compared to those treated with each single drug. ABT737 abrogated the protection from BIO-induced apoptosis provided by MS5 coculture.

     

     

    Exp Hematol 2010 38, 908-921. ABT-737 purchased from Selleck.

  • The combined use of ABT-737 and sorafenib changes the apoptotic effect. MC-3 cells were treated with the indicated compounds for 48 h. (A) Nuclear condensation and fragmentation were evaluated in DAPI-stained cells as described in the Materials and Methods (X400). (B) Live (green) and dead (red) cells were qualified using the Live/dead assay kit as described in the Materials and Methods (X200). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Arch Oral Biol, 2017, 73:1-6. ABT-737 purchased from Selleck.

    MEF wt and MEF Mcl-1 ko mice activating active caspase-3 using 1um ABT for 24h

     

     

    Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck.

  • MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100nm ABT-737.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
Features First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Targets
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50)
In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  NFvFc2JE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFnHPWkzPTBibl5CpC=> MojHO|IhcA>? M2\GW2ROW09? M2L2VoNifXOnZDC5O{UhdG:|czDv[kB3cWGkaXzpeJkhcW5iY3XscJMhfHKjboPm[YN1\WRid3n0bEBDS0x4IIPpVm5C M1PmOVI3PjV5Mki4
KG1a MYLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGn2flIxNTFyIN88US=> Mk\5NlQhcA>? M1vUcWROW09? MVnJR|UxRTdwNkig{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1zrdFI3PTV{N{Gy
Kasumi-1 NWrOcVRTS2WubDDWbYFjcWyrdImgRZN{[Xl? M2qyU|AuOTBizszN NVfkdoxJOjRiaB?= MYPEUXNQ NGfXcm9KSzVyPUSuPFch|ryPLDDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmnCNlY2PTJ5MUK=
KG1a Ml3TRZBweHSxc3nzJGF{e2G7 MnW5NE0yOCEQvF2= MWKyOEBp NIKzcphFVVOR NXuyPJBkcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MV[yOlU2OjdzMh?=
Kasumi-1 MXHBdI9xfG:|aYOgRZN{[Xl? MnLVNE0yOCEQvF2= M4\oPVI1KGh? MU\EUXNQ NELVOGFqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MmTONlY2PTJ5MUK=
MC-3  NH7ZdFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXXOU8yOC9{MDFOwG0> MnLONlQhcA>? MW\EUXNQ NVG4bmxpcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWmyOlQ1PzZzNR?=
HN22  M370N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL1fW9yOi53L{euOU8zOi53IN88US=> MVmyOEBp NGnrRYlFVVOR M2Xn[4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MXGyOlQ1PzZzNR?=
MC-3  NHTjfo9CeG:ydH;zbZMhSXO|YYm= MmGxOU8yOC9{MDFOwG0> MnjaNlQhcA>? NF;0dpRFVVOR M2fkXYlv\HWlZYOgZ4F{eGG|ZT3t[YRq[XSnZDDhdI9xfG:|aYO= NVTs[GhHOjZ2NEe2NVU>
HN22  NUTvTYRCSXCxcITvd4l{KEG|c3H5 MmfVNk42NzdwNT:yNk42KM7:TR?= M4f5NFI1KGh? NYLNdVByTE2VTx?= NEDmSXZqdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz MkXqNlY1PDd4MUW=
MOLT-4 NG\ZZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfwNVAuPTByMDDuUS=> MnnxO|IhcA>? M1LuNmROW09? NVy0UYtNUUN3ME2wMlE6QCEQvF2= NGSxXYIzPjN7MkOzNi=>
RS4;11 NGjkeoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDDdYMyOC13MECwJI5O Mlz4O|IhcA>? MkftSG1UVw>? NYXJSnhyUUN3ME2wMlAxOiEQvF2= NHfRSJQzPjN7MkOzNi=>
JURKAT NEizXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUexNE02ODByIH7N M3zKdVczKGh? M1:0SmROW09? NFPO[otKSzVyPU[2JO69VQ>? M{jEd|I3Ozl{M{Oy
CEM R NWq4PZJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[4UXdIOTBvNUCwNEBvVQ>? M1nOXVczKGh? M{LtU2ROW09? Mk\BTWM2OD13LkSg{txO Ml7BNlY{QTJ|M{K=
CEM S NF[xWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2xNE02ODByIH7N MmnrO|IhcA>? NU[ybW84TE2VTx?= M3zT[GlEPTB;MUKuNUDPxE1? MWiyOlM6OjN|Mh?=
MOLT-4 MVPBdI9xfG:|aYOgRZN{[Xl? M2\rdFExNTFyMECgcm0> NGXjZm4zPCCq NVfOOYFsTE2VTx?= MYnjZZV{\XNidHjlJINt\WG4YXflJI9nKEKlbD2yJIFv\CC2aHWg[I94dnKnZ4XsZZRqd25ib3[gRoNtNXiOIHHu[EBO[2xvMR?= MnfqNlY{QTJ|M{K=
CEM S NWPiS4l5SXCxcITvd4l{KEG|c3H5 Mn31NVAuOTByMDDuUS=> NFzOepgzPCCq NXzJTmw4TE2VTx?= MlPWZ4F2e2W|IITo[UBkdGWjdnHn[UBw\iCEY3ytNkBidmRidHjlJIRwf26{ZXf1cIF1cW:wIH;mJGJkdC26TDDhcoQhVWOuLUG= M3qxVVI3Ozl{M{Oy
JURKAT Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m3flExOC1zMECwJI5O MljBOFghcA>? NYTzTHBWTE2VTx?= NF\rRpNKSzVyPUm1OeKyQS5|IH7N Mn36NlYyPzJ{Nkm=
LOUCY MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr0XHEyODBvMUCwNEBvVQ>? MkDJOFghcA>? MUHEUXNQ MYfJR|UxRTN{LklCtVExNjlibl2= NUXzUGx[OjZzN{KyOlk>
WM-115 NFnzeotE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYqxNFDDqG6P NIjhbnc4OiCq NFfoR49mdmijbnPld{BkfXKldX3pck1qdmS3Y3XkJIFvfGlvc4Xyeol3[W{EoB?= MmLBNlYyOTZ5N{[=
B16 NV7L[XpUS2WubDDWbYFjcWyrdImgRZN{[Xl? NWHhfHNjOTBywrDuUS=> M1fYdlczKGh? NVHBSJd[\W6qYX7j[ZMh[3W{Y4XtbY4ucW6mdXPl[EBidnSrLYP1dpZqfmGuwrC= M{LjTFI3OTF4N{e2
HL-60  NIP1W5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfKd49zPzJiaB?= MVzJR|UxyqB;IEGwMlchdk1? M1zMfFI3ODR3NkC5
MOLM-13  MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jkb|czKGh? M{e3[WlEPTEEoE2gNlcvQSCwTR?= NFjQW20zPjB2NU[wPS=>
OCI-AML3 Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X5TVczKGh? M1yxUGlEPTEEoE2gNVk2OCCwTR?= NVz3fFg2OjZyNEW2NFk>
BCWM.1 MnvaRZBweHSxc3nzJGF{e2G7 NFHkfpIxNTFwNjFOwG0> NEHlfoszPCCq NHfVUIZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M2HYO|I2QDl|Mkmw
MWCL-1 MlzlRZBweHSxc3nzJGF{e2G7 M2m5bVAuOS54IN88US=> NWXBW|hzOjRiaB?= M{jYXYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MX:yOVg6OzJ7MB?=
MM.1s MWnBdI9xfG:|aYOgRZN{[Xl? MWOwMVEvPiEQvF2= NXfhbpBHOjRiaB?= NHHNd2hqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MUmyOVg6OzJ7MB?=
HCT116 MmHOSpVv[3Srb36gRZN{[Xl? M2fJVlMwOTBizszN MmHiNVLDqGkEoB?= NWHrWpJoTE2VTx?= NXfsUoxocW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKEyFM1KtTWkh[2:wdnXyd4lwdiCjbnSgV3FUXE1zIHTl[5Ji\GG2aX;u M3Hoc|I2PzF3MEK4
HCT116 BAX BAK1 DKO NE\TNXZHfW6ldHnvckBCe3OjeR?= MUSzM|ExKM7:TR?= MkPXNVLDqGkEoB?= NIDCZllFVVOR NXf0[I8zcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKEyFM1KtTWkh[2:wdnXyd4lwdiCjbnSgV3FUXE1zIHTl[5Ji\GG2aX;u M3W3cVI2PzF3MEK4
HCT116 MWPGeY5kfGmxbjDBd5NigQ>? MlzwNVAh|ryP NIXYR3EyOsLiaNMg NWTab3lSTE2VTx?= MYjpcoNz\WG|ZYOgS2ZRNUyFM1KgdJVv[3Sj NHnpZZczPTdzNUCyPC=>
HCT116 BAX BAK1 DKO M{jDRWZ2dmO2aX;uJGF{e2G7 MnHYNVAh|ryP MYGxNuKhcMLi M4TXTWROW09? MoDSbY5kemWjc3XzJGdHWC2OQ{PCJJB2dmO2YR?= NHjjZ4gzPTdzNUCyPC=>
HCT116 NGnaS5RCfXSxcHjh[5khSXO|YYm= NUnwbIlyOTBizszN MU[xNuKhcMLi NF\2cYVFVVOR NFjJXpdqdmS3Y3XzJIEh[2:vcHzleIUh[XW2b4DoZYdq[yC{ZYPwc45{\Q>? MWKyOVcyPTB{OB?=
HCT116 BAX BAK1 DKO NG\OPZZCfXSxcHjh[5khSXO|YYm= NEH2b2MyOCEQvF2= M{K3flEzyqCqwrC= NIXoXZZFVVOR NXTxTWpCcW6mdXPld{BiKGOxbYDs[ZRmKGG3dH;wbIFocWNicnXzdI9ve2V? NGfEXnIzPTdzNUCyPC=>
U937 MlSyRZBweHSxc3nzJGF{e2G7 NVzaVo03OC5zMkWtNkDPxE1? MVSyOEBp NFjBWmlmdmijbnPld{BFUEFxWD2xNU1qdmS3Y3XkJIFxd3C2b4Ppdy=> MnPmNlU4OTRyMkS=
U937  NYTSSlhPSXCxcITvd4l{KEG|c3H5 NVXySpZCOC53IN88US=> MX2yOEBp MVLlcohidmOnczDjcIVifmGpZTDv[kBRSVKSIHHu[EBk[XOyYYPlMVMh[XNid3XscEBieyCQb4jhJIxmfmWu M{PvNlI2PzF2MEK0
HL-60 AAA-Bcl-2 MYjBdI9xfG:|aYOgRZN{[Xl? MmXrNE02KM7:TR?= NUjMU4dlPDhiaB?= NHn3c3ZKSzVyPUCuPFch|ryv78{MbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MoXlNlU4OTF2NkC=
HL-60 EEE-Bcl-2 NF\WfWdCeG:ydH;zbZMhSXO|YYm= MkXWNE02KM7:TR?= NXXwd4FuPDhiaB?= MWrJR|UxRTVizszt89yNKGmwZIXj[ZMh[2WubDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MmrRNlU4OTF2NkC=
U87 MXrGeY5kfGmxbjDBd5NigQ>? M3HCeFUxKM7:TR?= M2rEO|I1KGh? MVHy[YR2[2W|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJG1OWC1{LDDNUXAuOTRiYX7kJGJkdC1{ MnS3NlU3Pjd4NkO=
K562 NFm2SodE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmC0NU0yOCEQvF2= MYO0PEBp MX3EUXNQ M4PLbGlEPTB;Mk[uO{DPxE1? NFSyTHAzPTV7NkW2NS=>
K562/Mcl -1-IRESBim NInweopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7UTWM2OD17LkOg{txO NXvMUJFpOjV3M{W5NFA>
K562/Bcl- 2-IRESBim NUX1bId2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwM{Wg{txO MnKzNlU2OzV7MEC=
Jurkat MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwNk[g{txO M3u4VFI2PTN3OUCw
JurkatΔBak MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRjVyIN88US=> Mnv1NlU2OzV7MEC=
HL60/VCR M{CwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3znO2lEPTB-MUCwJO69VQ>? NWfldJVLOjV3M{W5NFA>
Kasumi-1 M2nvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjKdYpKSzVyPUCuNFEh|ryP MnXjNlU2OzV7MEC=
Kasumi-1/ABT Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTSfFZ[UUN3ME2wMlUyKM7:TR?= NX7TWo1[OjV3M{W5NFA>
THP-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TXUGlEPTB;MT6yO{DPxE1? MVqyOVU{PTlyMB?=
U937 MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\UU2lEPTB;NT6yPUDPxE1? NHPaTGMzPTV|NUmwNC=>
C1498 M1rDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnaTWM2OD14LkGzJO69VQ>? NIiyPHEzPTV|NUmwNC=>
RPMI 8226 MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMkWg{txO NUXLbVFoOjV3M{W5NFA>
MM.1S NXO3eGh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwNECg{txO NGWxUYYzPTV|NUmwNC=>
NCI-H929 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3qTWM2OD1zNT6yNUDPxE1? NWO1U|VNOjV3M{W5NFA>
U266 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[wTWlEPTB;MD62PEDPxE1? M2[0PFI2PTN3OUCw
MCF-7 MlvDR4VtdCCYaXHibYxqfHliQYPzZZk> M{HsWlUh|ryP M2Hk[|Q5KGh? Ml7qSG1UVw>? NH\Xe4hmdmijbnPld{B1cGVic3Xud4l1cX[rdImgeI8hd3JicnHkbYF1cW:w MkDPNlU1ODlzMkS=
MCF-7 MWrBdI9xfG:|aYOgRZN{[Xl? NFjoc2k2KM7:TR?= NH;m[Vg1NzJ2L{S4JIg> NI[xW4VFVVOR NHLRdpNqdmO{ZXHz[ZMhfGinIHPs[YF3\WRiUFHSVC=> NUnkeml{OjV2MEmxNlQ>
MCF-7 M33MU2Z2dmO2aX;uJGF{e2G7 M3G3bFUh|ryP M{fTTVI1KGh? M1K1SmROW09? MnnB[Y5p[W6lZYOgeIhmdGW4ZXygc4YhVWOuLUGg[ZhxemW|c3nvcuKh NI\vb40zPTRyOUGyOC=>
MDA-MB 231  MknESpVv[3Srb36gRZN{[Xl? MoDpOUDPxE1? MlTsNlQhcA>? NYO2[|ZiTE2VTx?= M2XmVoVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>? Ml3aNlU1ODlzMkS=
ZR-75-1  MVXGeY5kfGmxbjDBd5NigQ>? M1yzdVUh|ryP M4\qTFI1KGh? MmfiSG1UVw>? NVHCRpJz\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi MmHNNlU1ODlzMkS=
A549 NHjXNJhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYPVPYV6OC1{MDFOwG0> MVy3NkBp Mk\5SG1UVw>? NGXiboZl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw NEXmZoQzPTN6OEe2Ni=>
H1299 M2jKZWNmdGxiVnnhZoltcXS7IFHzd4F6 Mm\TNE0zOCEQvF2= NGK5VVM4OiCq Ml2xSG1UVw>? NUjsdWYz\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= Mn;vNlU{QDh5NkK=
HO-8910 MVnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Ml2wNE0zOCEQvF2= NVfnSJpOPzJiaB?= Ml3aSG1UVw>? NILYcoNl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw NFXQZ|AzPTN6OEe2Ni=>
HT-29 NGrsOIlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXewMVIxKM7:TR?= NXLPWFQ6PzJiaB?= MorrSG1UVw>? NGLIe3Fl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw MXOyOVM5QDd4Mh?=
HCT-116 MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3rRZVAuOjBizszN Mm\FO|IhcA>? M3PXbmROW09? MYnk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv NFjpfXYzPTN6OEe2Ni=>
A549 MWnBdI9xfG:|aYOgRZN{[Xl? MnHXNlAh|ryP MoPFOFghcA>? MWrEUXNQ NF3Dc2lqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIgh[XOyaYLpci=> Ml7uNlU{QDh5NkK=
H1299 MoG5RZBweHSxc3nzJGF{e2G7 M3j0TFIxKM7:TR?= Mmj3OFghcA>? M{T0VmROW09? MYjpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigZZNxcXKrbh?= M2LKXFI2Ozh6N{[y
Sc-1 M4jKZWNmdGxiVnnhZoltcXS7IFHzd4F6 NHjVeosxNjByMEGtNUDPxE1? M4L2bVk3KGh? NWHwfJV[\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NF3DW5YzPTN5M{WwPC=>
OcI-LY18 M3PVe2NmdGxiVnnhZoltcXS7IFHzd4F6 MkDDNE4xODBzLUGg{txO NV7T[G51QTZiaB?= MXHk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NVK1VJhvOjV|N{O1NFg>
RL  NYLlXosxS2WubDDWbYFjcWyrdImgRZN{[Xl? MnLJNE4xODBzLUGg{txO NXjZcZFGQTZiaB?= NUnndXcx\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4DOdlI2Ozd|NUC4
RKO NF\M[llE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MoXHNE0yOCEQvF2= NUT0fWZTOjUkgJnoxsA> M1:1XWROW09? M1fydGlEPTB-4pEJNlXjiIoEtV2= MlHiNlU{ODR|OEO=
Caco-2 NULZVY1zS2WubDDWbYFjcWyrdImgRZN{[Xl? Mlr0NE0yOCEQvF2= MlLkNlTjiImqwrC= MnXjSG1UVw>? Mnu4TWM2OD1zOT635qCKyrWP M1LrdFI2OzB2M{iz
DLD1 Mn3DR4VtdCCYaXHibYxqfHliQYPzZZk> M3jMUVAuOTBizszN NUnsR|VCOjUkgJnoxsA> MVzEUXNQ NFz3NopKSzVyPUG4Mlc56oDLwsXN M{DpW|I2OzB2M{iz
LS411N M2TMeGNmdGxiVnnhZoltcXS7IFHzd4F6 MXiwMVExKM7:TR?= MV[yOQKBkWkEoB?= MWHEUXNQ MlS1TWM2OD1zMT60O-KBkcL3TR?= NYrXW3V{OjV|MESzPFM>
SW620 NVTZSod[S2WubDDWbYFjcWyrdImgRZN{[Xl? NUX0Omg1OC1zMDFOwG0> Ml3yNlTjiImqwrC= NYi0VJpsTE2VTx?= NI\5cWJKSzVyPUGyMlI16oDLwsXN MXGyOVMxPDN6Mx?=
HCT116 NYTvbmJTS2WubDDWbYFjcWyrdImgRZN{[Xl? NXXqR4pmOC1zMDFOwG0> NXvqUodtOjUkgJnoxsA> M1S3dWROW09? MoXpTWM2OD1{MD60PgKBkcL3TR?= M4ewPFI2OzB2M{iz
HaCaT MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NH6yRXgxNjFxMT:xNEDPxE1? M3v1UlI1KGh? MYXEUXNQ NUfPbmhE\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NWm3N|JROjV{MUC3PVU>
A5-RT3 NVnSWlJoS2WubDDWbYFjcWyrdImgRZN{[Xl? NYTud3A1OC5zL{GvNVAh|ryP M2LhSVI1KGh? MkOySG1UVw>? MmPE[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MWmyOVIyODd7NR?=
HaCaT NYX6NXU4TnWwY4Tpc44hSXO|YYm= MkO1NVDjiIoQvF2= Mn7JNlQwPDhiaB?= MW\EUXNQ NVf6[YZEcW6mdXPld{BOVVBiYX7kJGRPSSCocnHncYVvfGG2aX;u NXm4UlhOOjV{MUC3PVU>
A5-RT3 M{TsdGZ2dmO2aX;uJGF{e2G7 NV3VdlgzOTEkgJpOwG0> MkXsNlQwPDhiaB?= MnXRSG1UVw>? MnvKbY5lfWOnczDNUXAh[W6mIFTORUBnemGpbXXueIF1cW:w M4\4RVI2OjFyN{m1
A5-RT3 MU\GeY5kfGmxbjDBd5NigQ>? NWDvZ5RrPSEQvF2= MoHYOkBp Mn;5SG1UVw>? M{XDV4lv\HWlZYOgeIhmKHKnbHXhd4Uhd2ZibXn0c4Npd26mcnnhcEBxem:2ZXnud{BidmRicnXkeYNmeyClbH;uc4dmdmmlIIP1dpZqfmGuIHnuJIEh[2G|cHHz[U1qdmSncHXu[IVvfCCvYX7u[ZI> NXXxOYFZOjV{MUC3PVU>
U266 MmnRSpVv[3Srb36gRZN{[Xl? MlPPOVAxNzd3MDDuUS=> M33HR|I1NzR6IHi= MlO3SG1UVw>? NEnz[2tld3ewcnXneYxifGW|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm|b3\vdo0> M3Pje|I2OjB6OEi4
RPMI8226 MUTGeY5kfGmxbjDBd5NigQ>? MYe1NFAwPzVyIH7N NUHZUohsOjRxNEigbC=> M4L6O2ROW09? NH\wNo5ld3ewcnXneYxifGW|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm|b3\vdo0> MnPENlUzODh6OEi=
MM.1S NIPFeYZHfW6ldHnvckBCe3OjeR?= Mo\xOVAxNzd3MDDuUS=> MWWyOE81QCCq M4DsTWROW09? NXzsSpA5\G:5boLl[5Vt[XSnczDCbY0tKHC{aX7jbZBidGy7IITo[UBGVCCrc3;mc5Ju Ml:2NlUzODh6OEi=
Clone A Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\ONE4z6oDVNkCg{txO NF3Lb2c4OiCq Mlz4SG1UVw>? MoThTWM2OD15LkWg{txO NXzZbHoyOjV{MEi4PFI>
CX-1 MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j1flAvOuLCk{[wJO69VQ>? NGnPVXc4OiCq M1jLRmROW09? MXTJR|UxRTFwODFOwG0> M3v3VVI2OjB6OEiy
LS174T MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nWPFAvOuLCk{[wJO69VQ>? NIjFZ|c4OiCq MV3EUXNQ NH7m[IdKSzVyPUG4MlMh|ryP NEf3bm0zPTJyOEi4Ni=>
HT29 NWD4RZp1SXCxcITvd4l{KEG|c3H5 NYjhZpVJOS93L{GwJO69VQ>? M1fT[lQ5KGh? NEDvRYNk[XW|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M3\hclI2OTl{MUi4
SW480 NEnvRpdCeG:ydH;zbZMhSXO|YYm= MWOxM|UwOTBizszN MVm0PEBp NHPkdJFk[XW|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NIn3ZmUzPTF7MkG4PC=>
Colo205 NHPlSItCeG:ydH;zbZMhSXO|YYm= NHXiR|MyNzVxMUCg{txO M2DYb|Q5KGh? NGrse5Jk[XW|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGrIVGUzPTF7MkG4PC=>
Caco2 NI\QPXVCeG:ydH;zbZMhSXO|YYm= NULpOoNbOS93L{GwJO69VQ>? NF7IZmM1QCCq MX3jZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MlzINlUyQTJzOEi=
PCI-13 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTTfllIPzJiaB?= MmnKSG1UVw>? MoDpS2k2OD1zNTFCtUAyNjhizszN MoC0NlUyOzl|OEe=
PCI-15B MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\sO|IhcA>? M3\kV2ROW09? NXjJbVU5T0l3ME2xNUDDuSB2LkWg{txO NXzWPJRPOjVzM{mzPFc>
UM-SCC22B NF:3Rm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPvWHN4PzJiaB?= M4rCV2ROW09? NV\GfmplT0l3ME2xPUDDuSB{Lkmg{txO NV\RWWI2OjVzM{mzPFc>
UM-SCC47 NGPGOopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\aWFczKGh? MYnEUXNQ NIrPcY1IUTVyPUG5JOKyKDF{LkOg{txO NIm1W2ozPTF|OUO4Oy=>
93-VU-147T M36z[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLN[Zg2PzJiaB?= NUf4bnNuTE2VTx?= NI\pfmlIUTVyPUSuN{DDuSB|LkWg{txO MX[yOVE{QTN6Nx?=
UD-SCC2 NUe1VndwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfCbYI4OiCq Mmr6SG1UVw>? NXr1d4FzT0l3ME2yPEDDuSB{Lkmg{txO NWj6cI9YOjVzM{mzPFc>
UPCI:SCC90 NUXtSJp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVi3NkBp M4Hj[2ROW09? NGLCdJdIUTVyPU[uOkDDuSBzLkWg{txO NV\ZeVBqOjVzM{mzPFc>
RPMI-8226  MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2r0V|EzPS9{NUCvOVAxKG6P MX20PIjDqA>? NX2zd3JETE2VTx?= NWPDVJds\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MnLxNlUxODh{MEK=
OPM-2  NHXt[4NE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXjSRWR1OTJ3L{K1NE82ODBibl2= NHzwdlI1QGkEoB?= MmG4SG1UVw>? NH7DVHhl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MXmyOVAxQDJyMh?=
RPMI-8226  MXrBdI9xfG:|aYOgRZN{[Xl? NHXYZ5MyOjVxMkWwM|UxOCCwTR?= NFrqd4s1QGkEoB?= NU\LXYFrTE2VTx?= MkDtbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlWyNlUxODh{MEK=
OPM-2  MXvBdI9xfG:|aYOgRZN{[Xl? Mni4NVI2NzJ3MD:1NFAhdk1? MlT5OFhpyqB? NXfZdmsxTE2VTx?= M1nM[olv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NX64XVRROjVyMEiyNFI>
COG-LL-319 MX\GeY5kfGmxbjDBd5NigQ>? M{DwW|ExOCCwTR?= NHjHZmcyNzNxNjDo M{XIXWROW09? MV;pcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IF3jcE0yKGOuZXH2ZYdm MYKyOFk2OTR5Mh?=
RS4;11 NHXIOpZHfW6ldHnvckBCe3OjeR?= NIXrU3gyODBibl2= M{j1fVEwOy94IHi= NYPOfYM6TE2VTx?= MkO2bY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDNZ4wuOSClbHXheoFo\Q>? MofkNlQ6PTF2N{K=

... Click to View More Cell Line Experimental Data

In vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence polarization assays:

Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research:

[4]

+ Expand
  • Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48 hours
  • Method:

    SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
  • Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
  • Dosages: 20 and 30 mg/kg
  • Administration: For intraperitoneal (i.p.) every day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (122.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% Propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 813.43
Formula

C42H45ClN6O5S2

CAS No. 852808-04-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommended method about reconstitution of the compound for in vivo animal study?

  • Answer:

    For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID